safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-302Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESКачественные методы определения отношения польза / риск фарКачественные методы определения отношения польза / риск фармакотерапииQualitative methods of benefit / risk assessmentПереверзевА. П.PereverzevA. P.МироновА. Н.MironovA. N.БунятянН. Д.BunyatyanN. D.ЛепахинВ. К.LepakhinV. K.РомановБ. К.RomanovB. K.Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииРоссияScientific Centre for Expert Evaluation of Medicinal Products Russian FederationRussian Federation201401062022022227Copyright © Переверзев А.П., Миронов А.Н., Бунятян Н.Д., Лепахин В.К., Романов Б.К., 20222022Переверзев А.П., Миронов А.Н., Бунятян Н.Д., Лепахин В.К., Романов Б.К.Pereverzev A.P., Mironov A.N., Bunyatyan N.D., Lepakhin V.K., Romanov B.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/302

В статье представлено описание некоторых современных методов оценки потенциальной пользы и возможных рисков фармакотерапии.

In this article authors describe some existing methods of benefit / risk assessment.

отношение польза/рискфармакотерапияbenefit/riskassessmentpharmacotherapyReferencesBelton, V. & Stewart, T. J. Multi ple Criteria Decision An alysis: An Integrated Approach (Kluwer, Boston, MA, 2001).Belton, V. & Stewart, T. J. Multi ple Criteria Decision An alysis: An Integrated Approach (Kluwer, Boston, MA, 2001).Benefit-risk methodology project: Work package 2 report EMA/549682/2010.Benefit-risk methodology project: Work package 2 report EMA/549682/2010.Bennett Levitan, Fili p Mussen. Evaluating benefit-risk during and beyond drug development: an industry view. Regulatory Rapporteur – Vol 9, No 6, June 2012.Bennett Levitan, Fili p Mussen. Evaluating benefit-risk during and beyond drug development: an industry view. Regulatory Rapporteur – Vol 9, No 6, June 2012.Bennett Levitan, Intern ation al Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting, May 24, 2011.Bennett Levitan, Intern ation al Society for Pharmacoeconomics and Outcomes Research 16th Annual Meeting, May 24, 2011.BS Levitan et al. ‘Application of the BRAT Framework to Case Studies: Observations and Insights’, Clin Pharmacol Ther, 89, 217-224, 2011.BS Levitan et al. ‘Application of the BRAT Framework to Case Studies: Observations and Insights’, Clin Pharmacol Ther, 89, 217-224, 2011.CHMP working group on benefit – risk assessment methods, 2008.CHMP working group on benefit – risk assessment methods, 2008.DIR 2001/83/EC Art 1(28a); DIR 2001/83/EC Art 1(28).DIR 2001/83/EC Art 1(28a); DIR 2001/83/EC Art 1(28).Dodgson, J.S., Spackman, M., Pearman, A., & Philli ps, L.D. Multi-Criteria An alysis: A Manual (Department for Communities and Local Government, London, 2009).Dodgson, J.S., Spackman, M., Pearman, A., & Philli ps, L.D. Multi-Criteria An alysis: A Manual (Department for Communities and Local Government, London, 2009).Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit an alysis of a medicine? Drug Saf. 1996 Jul;15(1):1-7.Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit an alysis of a medicine? Drug Saf. 1996 Jul;15(1):1-7.Keeney, R.L. & Raiffa, H. Decisions with Multi ple Objectives: Preferences and Value Tradeoffs (Cambridge University Press, NY, 1993).Keeney, R.L. & Raiffa, H. Decisions with Multi ple Objectives: Preferences and Value Tradeoffs (Cambridge University Press, NY, 1993).Leviatan, B. A concise display of multi ple end points for benefit-risk assessment. Clin. Pharmacol. Ther. (2010); e-pub ahead of print 24 November 2010.Leviatan, B. A concise display of multi ple end points for benefit-risk assessment. Clin. Pharmacol. Ther. (2010); e-pub ahead of print 24 November 2010.PM Coplan, RA Noel, BS Levitan, J Ferguson and F Mussen, Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines. Clin Pharmacol Ther, 89, 312-315, 2011.PM Coplan, RA Noel, BS Levitan, J Ferguson and F Mussen, Development of a Framework for Enhancing the Transparency, Reproducibility and Communication of the Benefit–Risk Balance of Medicines. Clin Pharmacol Ther, 89, 312-315, 2011.

The authors declare that there are no conflicts of interest present.